Answers are grounded in this paper and cite their sources.
Background: Due to the COVID-19 pandemic, randomized clinical studies were conducted with Remdesivir in combination with Bariticinib or Dexamethasone, which have shown effectiveness for the treatment of COVID-19. Objective: We analyzed the effect of co-treatment with Remdesivir in a retrospective in Mexico. Methods: Thirty-four patients treated with Remdesivir in combination with Baricitinib or Dexamethasone were included. Age, sex, comorbidities, signs, and symptoms were recorded at hospital admission, intubation needs, intensive care unit (ICU) requirements, days of hospital stay and their evolution, as well as laboratory data upon admission and upon admission terminate Remdesivir treatment. Results: Most were male, with an age of 56.5 years (49 years-60.3 years), whose main comorbidity was obesity. The main symptoms on admission were dyspnea and cough. Thirty-two patients received the short Remdesivir regimen, 22 were co-treated with Baricitinb and 12 with Dexamethasone. Most did not require ICU care, 9 patients died, 19% of those co-treated with Baricitinib and 42% of those co-treated with Dexamethasone. A significant decrease in hemoglobin, protein, albumin and LDH levels was observed. Conclusion: In this study, we observed lower mortality in patients co-treated with Baricitinib vs those co-treated with Dexamethasone, and a hospital stay similar to that reported in randomized clinical studies.
No takes yet. Share an insight, caveat, or question.
García-Araiza et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: